IL1B and gout: The possibility that epigenetic mechanisms may contribute to gout pathogenesis offers the potential of a set of completely different therapeutic options and, more importantly, lasting management of patients through epigenetic reprogramming of innate immune cells such as monocytes/macrophages (for instance with the Histone DeAcetylase -HDAC - inhibitor Vorinostat), which are the main producers of Il-1β, a crucial cytokine in gout pathogenesis.